利拉鲁肽早期和长期应用为2型糖尿病综合管理带来益处

摘要

[Summary] Treatment of type 2 diabetes which is characterized by the progressive β-cell dysfunction currently faces various challenges.A new generation of drug need to protect β-cell function in early stage of the disease.Liraglutide is a glucagon-like peptide 1 analogue and provides a new therapeutic option due to its unique clinical efficacy.Early and long-term usage of liraglutide improves glycemic control,reduces body weight and systolic blood pressure,as well as protects β-cell function for the patients with diabetes.%2型糖尿病以β细胞功能的进行性衰竭为特点,其治疗面临多重挑战.新型治疗药物应针对2型糖尿病的病理生理机制,早期对β细胞进行保护.胰升糖素样肽1(GLP-1)类似物利拉鲁肽具有独特的临床疗效,早期和长期使用为患者带来降糖、减轻体重、降低收缩压、保护β细胞等多方面收益,为2型糖尿病综合治疗提供了新的选择.